Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 288

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 288
---
 • |     | monitoring and recommending modifications to Semnur’s insider trading policy, if necessary or advisable, to the Board. |

The Nominating and Corporate Governance Committee periodically reviews, discusses and assesses the performance of the Board and the committees of the Board. In fulfilling this responsibility, the Nominating and Corporate Governance Committee seeks input from senior management, the Board and others. In assessing the Board, the Nominating and Corporate Governance Committee evaluates the overall composition of the Board, the Board’s contribution as a whole and its effectiveness in serving Semnur’s best interests and the best interests of Semnur’s stockholders. The Nominating and Corporate Governance Committee reviews, discusses and assesses its own performance and composition at least annually. The Nominating and Corporate Governance Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to the Board for its consideration and approval. The composition and functioning of the nominating and corporate governance committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. Semnur intends to comply with future requirements to the extent they become applicable to Semnur. Commercialization and Transaction Committee Semnur’s commercialization and transaction committee (the “C&T Committee”) consists of Jay Chun, M.D., Ph.D., Jaisim Shah, and Henry Ji, Ph.D. The responsibilities of the C&T Committee are included in its written charter. The C&T Committee’s responsibilities include, among others, the following commercialization matters:

| • |     | providing strategic, directional and operational oversight and guidance to the Company regarding its commercial activities and operations; |

| • |     | evaluating the alignment of the Company’s commercial and R&D programs and progress with the Company’s strategic goals and objectives, taking into account the results of the Company’s pre-clinical studies and clinical trials; |

| • |     | overseeing periodic reviews of the Company’s product development pipeline, intellectual property portfolio and commercial strategies, including a review and analysis of the progress and results of the Company’s pre-clinical studies and clinical trials; |

186

| • |     | overseeing key commercial and medical launch strategies prior to regulatory approval of new products or indications as well as the R&D elements of the Company’s long-range plan and lifecycle management plans; |

| • |     | overseeing management on the scientific and R&D aspects of business development opportunities, including